Four Analysts Set NZD 3.07 Target for Ryman Healthcare Stock

Published on 10/20/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Four analysts set a NZD 3.07 average target for November 2026. Ryman Healthcare stock costs EUR 0.91 on October 20, 2026 at Lang & Schwarz.

Analysts and operating figures

Four analysts place the average Ryman Healthcare target at NZD 3.07 for November 2026.
Second-quarter FY27 sales reached 379 occupation right agreements, while resales rose 14.00 percent year on year.
Ryman Healthcare stock costs EUR 0.91 at Lang & Schwarz on October 20, 2026 at 9:36 p.m. CEST, with a 52-week high of NZD 3.05.

RYM, NZRYME0001S4, Illustration mit AI erstellt.

Ryman Healthcare (ISIN NZRYME0001S4) has a four-analyst average target of NZD 3.07 for November 2026, according to Simply Wall St in an update dated October 17, 2026. The target is 67.76 percent above the NZD 1.83 share price used in that table. Ryman Healthcare stock was at EUR 0.91 at Lang & Schwarz on October 20, 2026 at 9:36 p.m. CEST.

Second-quarter sales reached 379

The operating picture improved in the second quarter of fiscal 2027. The Globe and Mail reported on October 12, 2026 that Ryman completed 379 retirement living occupation right agreement sales. Resales rose 14.00 percent year on year to an eight-quarter high, while net resale contracts increased 11.00 percent.

The same report put total occupancy at 94.00 percent and inventory at 347 units. Those figures give the analyst target a more tangible operating backdrop than the valuation table alone, although the article also cited a Hold rating and a NZD 2.56 target from the latest analyst view.

Stock remains below its yearly high

Ryman's NZX quotation was NZD 1.83 on October 20, 2026 at 5:00 p.m. NZDT, with a 52-week range of NZD 1.66 to NZD 3.05. The market capitalization was NZD 1.9 billion as of October 17, 2026, according to the Simply Wall St valuation page.

Ryman operates retirement villages and aged-care facilities in New Zealand and Australia. Its investor page describes an integrated model spanning independent living, assisted living and aged care across 47 villages, with more than 15,500 residents and 7,800 employees. The company is dual listed on the NZX and ASX.

Cash flow is the central valuation test

Ryman's fiscal 2026 operating revenue reached NZD 849 million, up 10.00 percent, while free cash flow reached NZD 188 million, according to Kurums in an October 4, 2026 review. Operating earnings before interest, tax, depreciation and fair-value movements rose 94.00 percent to NZD 88 million for the year ended March 31, 2026.

The comparison matters because the business had reported negative free cash flow through its earlier expansion cycle. The combination of positive cash generation and a target above the current NZD share price is the main investment tension visible in the latest figures.

Price and operating facts

Ryman Healthcare's euro quotation stood at EUR 0.91 at Lang & Schwarz on October 20, 2026 at 9:36 p.m. CEST. Its NZX share price was NZD 1.83 at 5:00 p.m. NZDT, while the 52-week high was NZD 3.05.

The further course of trading is shown by the continuously updated real-time quote of Ryman Healthcare stock.